Former EVP at Theramex HQ UK Ltd
- Pandemic impacts on the women’s health market and Theramex’s relative exposure based on portfolio composition and geographic exposure
- Theramex’s contraceptive, fertility, menopause and osteoporosis franchise analysis – key price and volume dynamics review and salient competitive threats
- Recent launches and in-licensing deals, including Livogiva (biosimilar teriparatide), Bijuva and Enzene Biosciences’ deal to develop and commercialise a biosimilar to Roche’s (VTX: ROG) Actemra (tocilizumab) in RA (rheumatoid arthritis)
Gain access to Premium Content
Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.